capecitabine has been researched along with Alopecia in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; Boot, H; Cats, A; Deenen, MJ; Legdeur, MC; Meulendijks, D; Schellens, JH | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS | 1 |
| Frye, DK | 1 |
| Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Akahane, T; Chiba, T; Hashimoto, Y; Yano, H | 1 |
| Iwase, S; Kitamura, K; Nagumo, Y; Odagiri, H; Yamamoto, C; Yamamoto, D | 1 |
| Andreetta, C; Cardellino, GG; Crivellari, D; Damante, G; Di Loreto, C; Lombardi, D; Magri, MD; Mansutti, M; Minisini, AM; Perin, T; Puglisi, F; Russo, S; Veronesi, A | 1 |
| Gordon, RJ; Osterwalder, B; Planting, AS; Pronk, LC; Reigner, B; Sparreboom, A; Twelves, C; Vasey, P; Verweij, J | 1 |
| Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R | 1 |
2 review(s) available for capecitabine and Alopecia
| Article | Year |
|---|---|
Capecitabine-based combination therapy for breast cancer: implications for nurses.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Paresthesia; Patient Compliance; Patient Education as Topic; Peripheral Nervous System Diseases; Prodrugs | 2009 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Monitoring; Fluorouracil; Home Care Services; Humans; Nausea; Neutropenia; Nurse's Role; Oncology Nursing; Patient Education as Topic; Safety; Stomatitis; Survival Rate; Treatment Outcome | 2004 |
7 trial(s) available for capecitabine and Alopecia
| Article | Year |
|---|---|
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Disease-Free Survival; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Fatigue; Female; Genetic Predisposition to Disease; Humans; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Polymorphism, Single Nucleotide; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Topoisomerase II Inhibitors; Treatment Outcome | 2008 |
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Genes, erbB-2; Heart Diseases; Humans; Infusions, Intravenous; Japan; Middle Aged; Trastuzumab; Treatment Outcome | 2008 |
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Carcinoma, Lobular; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Liver Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation | 2008 |
A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biotransformation; Capecitabine; Carboxylic Ester Hydrolases; Deamination; Deoxycytidine; Dexamethasone; Docetaxel; Drug Administration Schedule; Female; Fever; Fluorouracil; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Liver; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Paronychia; Prodrugs; Remission Induction; Taxoids; Treatment Outcome | 2000 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease Progression; Female; Fluorouracil; Humans; Injections, Intravenous; Leucovorin; Male; Middle Aged; Nausea; Stomatitis; Survival Analysis; Treatment Outcome | 2001 |
2 other study(ies) available for capecitabine and Alopecia
| Article | Year |
|---|---|
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
[A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Neoplasm Recurrence, Local; Quality of Life; Toremifene | 2007 |